Ve­rastem's stock takes a hit af­ter shar­ing up­dat­ed fil­ing plans in ovar­i­an can­cer

For a mo­ment, Ve­rastem On­col­o­gy looked like one of the ear­ly win­ners of the Amer­i­can So­ci­ety of Clin­i­cal On­col­o­gy’s an­nu­al meet­ing.

The com­pa­ny’s shares …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER